



**Appendix A**

**Claim Amendments**

1. - 4. (Canceled)

5. (Currently amended) A lipid-free pharmaceutical composition in powder form comprising a pharmaceutically acceptable active component and a suitable carrier therefore, wherein the active component comprises recombinant surfactant protein A (rSP-A).

6. (Currently amended) A method for ~~preventing~~ or treating a pulmonary infection in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 5.

7. (Previously presented) The method according to claim 6, wherein the pulmonary infection is bacterial, viral or fungal pneumonia.

8. (Currently amended) A method for ~~preventing or~~ treating a pulmonary inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 5.
9. (Previously presented) The method according to claim 8, wherein the pulmonary inflammation is bronchopulmonary dysplasia.
10. (Previously presented) The pharmaceutical composition of claim 5, wherein the rSP-A is obtained by expression of a genomic sequence coding for SP-A in a suitable expression system.
11. (Previously presented) The pharmaceutical composition of claim 5, wherein the rSP-A is obtained by expression of a cDNA coding for SP-A in a suitable expression system.

12. (Previously presented) The pharmaceutical composition of claim 5, wherein the active component further comprises surfactant protein D (SP-D).

13. (Currently amended) A method for ~~preventing or~~ treating a pulmonary infection or inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 5.

14. (Canceled)

15. (Currently amended) A method of ~~preventing or~~ treating a pulmonary infection or inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 12.

16. (Currently amended) An article of manufacture comprising packaging material and the pharmaceutical composition according to claim 5 contained within the

packaging material, wherein the packaging material comprises a label or package insert which indicates that the active component is useful for ~~preventing or~~ treating a pulmonary microbial infection or inflammation.

17. (Currently amended) An article of manufacture comprising packaging material and the pharmaceutical composition according to claim 12 contained within the packaging material, wherein the packaging material comprises a label or package insert which indicates that the active component is useful for ~~preventing or~~ treating a pulmonary microbial infection or inflammation.

18. (New) A method for treating a pulmonary infection in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a lipid-free pharmaceutical composition comprising a pharmaceutically acceptable active component and a suitable carrier therefore, wherein the active

component comprises recombinant surfactant protein A (rSP-A).

19. (New) The method according to claim 18, wherein the pulmonary infection is bacterial, viral or fungal pneumonia.

20. (New) A method for treating a pulmonary inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a lipid-free pharmaceutical composition comprising a pharmaceutically acceptable active component and a suitable carrier therefore, wherein the active component comprises recombinant surfactant protein A (rSP-A).

21. (New) The method according to claim 20, wherein the pulmonary inflammation is bronchopulmonary dysplasia.

22. (New) A method for treating a pulmonary infection or inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient

in need thereof a therapeutically effective amount of a lipid-free pharmaceutical composition comprising a pharmaceutically acceptable active component and a suitable carrier therefore, wherein the active component comprises recombinant surfactant protein A (rSP-A).

23. (New) A lipid-free pharmaceutical composition comprising a pharmaceutically acceptable active component and a suitable carrier therefore, wherein the active component comprises recombinant surfactant protein A (rSP-A) and further comprises surfactant protein D (SP-D).

24. (New) A method for treating a pulmonary infection in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 23.

25. (New) The method according to claim 24, wherein the pulmonary infection is bacterial, viral or fungal pneumonia.

26. (Currently amended) A method for treating a pulmonary inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 23.
27. (New) The method according to claim 26, wherein the pulmonary inflammation is bronchopulmonary dysplasia.
28. (New) A method of treating a pulmonary infection or inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 23.
29. (New) An article of manufacture comprising packaging material and the pharmaceutical composition according to claim 23 contained within the packaging material, wherein the packaging material comprises a label or package insert which indicates that the active component is useful for treating a pulmonary microbial infection or inflammation.